行情

TROV

TROV

Trovagene
NASDAQ

实时行情|Nasdaq Last Sale

1.520
-0.030
-1.94%
盘后: 1.540 +0.02 +1.32% 16:44 11/15 EST
开盘
1.420
昨收
1.550
最高
1.530
最低
1.420
成交量
47.51万
成交额
--
52周最高
9.65
52周最低
0.8800
市值
1,176.84万
市盈率(TTM)
-0.4575
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

TROV 新闻

  • Benzinga Pro's Top 5 Stocks To Watch For Thurs., Nov. 14, 2019: NVDA, SINA, DDS, TROV, AMRN
  • Benzinga.3天前
  • Trovagene up 17% premarket on positive onvansertib data
  • Seeking Alpha - Article.3天前
  • Trovagene Reports Data In Metastatic Prostate Cancer Phase 2 Trial: 72% Of Patients Had Decreases In PSA Levels, 60% Completed 3-Month Treatment
  • Benzinga.3天前
  • Trovagene Presents Positive Data in Metastatic Prostate Cancer Phase 2 Trial Showing Clinical Response in Patients Resistant to Zytiga®
  • PR Newswire.3天前

更多

所属板块

医疗设备、用品及经销
+1.05%
医疗设备和用品
+1.69%

热门股票

名称
价格
涨跌幅

TROV 简况

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers. PCM-075 developed high selectivity to PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase Ib/II clinical trial in patients with AML underway.
展开

Webull提供TrovaGene Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。